Avalyn Pharma Inc.
AVLN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVLN
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib).
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.54B
Cash Runway
40.2 moLead Asset
ap01 (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for Avalyn Pharma Inc..
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib).
- Cash and equivalents of $264.2M as of 2026-06-30 [sec].
- Net loss of $28.9M for the quarter ended 2026-06-30 [sec].
- Accumulated deficit of $265.4M as of December 31, 2025 [sec · filed 2026-04-08].
- Lead candidates AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib) are in clinical development [sec · filed 2026-04-08].
- Phase 2 topline data for AP01 expected by 2027-12-31 [upcoming catalysts].
What works
- Strong institutional investor backing from Novo Holdings, SR One, F-Prime, and others [sec · filed 2026-04-08].
- Experienced management team with deep biopharma and inhaled therapy expertise [sec · filed 2026-04-08].
- Cash runway of $264.2M as of 2026-06-30 supports ongoing clinical trials [sec].
What to weigh
- Significant accumulated deficit of $265.4M as of December 31, 2025, with no product revenue [sec · filed 2026-04-08].
- Operating losses expected to increase substantially as clinical development advances [sec · filed 2026-04-08].
- Clinical development is time-consuming, expensive, and uncertain; product candidates may never achieve regulatory approval [sec · filed 2026-04-08].
- Negative shareholders' equity of -$174.5M as of 2026-06-30 indicates financial risk [sec].
From the filings
Quoted directly from source documents.
Accumulated deficit of $265.4M as of December 31, 2025
“As of December 31, 2025, we had an accumulated deficit of $265.4 million.”
SEC filings · April 8, 2026
Lead candidates AP01 and AP02 are in clinical development
“continue to advance clinical development of our lead candidates, AP01 (inhaled pirfenidone), or AP01, and AP02 (inhaled nintedanib), or AP02”
SEC filings · April 8, 2026
Catalyst timeline
- 2027-12-31 · Phase 2 topline data for AP01 — Topline results from the Phase 2 trial of inhaled pirfenidone (AP01) are expected, which will inform further development and potential registration.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Avalyn has no products approved for commercial sale and has not generated any revenue from product sales [sec · filed 2026-04-08].
- Substantial operating losses expected — Expenses and operating losses are expected to increase substantially as clinical trials advance [sec · filed 2026-04-08].
- Clinical development uncertainty — Clinical trials are time-consuming, expensive, and may not yield positive results; product candidates may fail to obtain regulatory approval [sec · filed 2026-04-08].
- Negative shareholders' equity — Shareholders' equity was -$174.5M as of 2026-06-30, indicating accumulated losses exceed assets [sec].
What to watch
- Phase 2 topline data for AP01 expected by 2027-12-31 [upcoming catalysts].
- Cash burn rate and any future financing needs as clinical programs advance [sec · filed 2026-04-08].
- Progress of AP02 clinical development and any preclinical updates [sec · filed 2026-04-08].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Avalyn Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avalyn Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
40.2 months
D/E 0.07 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~488d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Avalyn Pharma Inc.?
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib).
What is Avalyn Pharma Inc.'s lead drug candidate?
Avalyn Pharma Inc.'s most advanced tracked candidate is ap01 (Phase 2) for Pulmonary Fibrosis.
What is Avalyn Pharma Inc.'s next catalyst?
Avalyn Pharma Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ap01" — expected December 31, 2027.
Who is the CEO of Avalyn Pharma Inc.?
Ms. Lyn Baranowski is the chief executive officer of Avalyn Pharma Inc. (AVLN).
Where is Avalyn Pharma Inc. headquartered?
Avalyn Pharma Inc. (AVLN) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.